Steroid derivatives as pure antagonists of the androgen receptor

Journal of Steroid Biochemistry and Molecular Biology

Volumn 132, Issue 1-2, 2012, Pages 93-104

  Gauthier, Sylvain ^a   Martel, Céline ^a   Labrie, Fernand ^a,b,c  

^a Endoresearch Inc   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c AL IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY IMSIU   (Saudi Arabia)

Author keywords

Androgen blockade; Androgen receptor; Antiandrogen; Bicalutamide; MDV3100; Prostate cancer

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ANDROGEN RECEPTOR ANTAGONIST; ANDROSTANOLONE; ANTINEOPLASTIC AGENT; BICALUTAMIDE; EM 5854; EM 5855; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN; STEROID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CARCINOMA CELL; CELL LINE; CELL PROLIFERATION; CELL STRAIN LNCAP; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EMBRYO; HUMAN; HUMAN CELL; MALE; MORNING DOSAGE; NONHUMAN; PROSTATE; PROSTATE CANCER; RAT;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; CELL LINE, TUMOR; FEMALE; HEK293 CELLS; HUMANS; MALE; MICE; ORGAN SIZE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, GLUCOCORTICOID; RECEPTORS, PROGESTERONE;

RATTUS; RODENTIA;

EID: 84864451273     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2012.02.006     Document Type: Article

References (88)

1. R. Siegel, E. Ward, O. Brawley, and A. Jemal Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J. Clin. 61 4 2011 212 236
2. F. Lichtenberg Measuring the health impacts of medical innovation and expenditure Health Services Research Seminal Series 2002-2003 2002 University of Minnesota Minneapolis, MN, USA
3. F. Labrie, A. Bélanger, L. Cusan, C. Séguin, G. Pelletier, P.A. Kelly, J.J. Reeves, F.A. Lefebvre, A. Lemay, and J.P. Raynaud Antifertility effects of LHRH agonists in the male J. Androl. 1 1980 209 228
4. R. Neri, M.D. Monahan, J.G. Meyer, B.A. Afonso, and I.A. Tabachnick Biological studies of an antiandrogen (SH-714) Eur. J. Pharmacol. 1 1967 438 444
5. F. Labrie, A. Dupont, and A. Bélanger Complete androgen blockade for the treatment of prostate cancer V.T. de Vita, S. Hellman, S.A. Rosenberg, Important Advances in Oncology 1985 J.B. Lippincott Philadelphia 193 217
6. F. Labrie Editorial: the major role of androgens in prostate cancer and the need for more efficient blockade Expert Rev. Endocrinol. Metab. 6 2011 313 316
7. F. Labrie Intracrinology Mol. Cell. Endocrinol. 78 1991 C113 C118
8. F. Labrie, A. Bélanger, V. Luu-The, C. Labrie, J. Simard, L. Cusan, J.L. Gomez, and B. Candas Gonadotropin-releasing hormone agonists in the treatment of prostate cancer Endocr. Rev. 26 3 2005 361 379 (Pubitemid 40686649)
9. B. Bélanger, A. Bélanger, F. Labrie, A. Dupont, L. Cusan, and G. Monfette Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men J. Steroid Biochem. 32 1989 695 698 (Pubitemid 19176012)
10. F. Labrie, L. Cusan, J.L. Gomez, C. Martel, R. Bérubé, P. Bélanger, A. Bélanger, L. Vandenput, D. Mellström, and C. Ohlsson Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer J. Steroid Biochem. Mol. Biol. 113 2009 52 56
11. F. Labrie Endocrinology and the prostate. Preface Best Pract. Res. Clin. Endocrinol. Metab. 22 2 2008 vii ix
12. F. Labrie Hormonal therapy of prostate cancer L. Martini, G.P. Chrousos, F. Labrie, K. Pacak, D.E. Pfaff, Neuroendocrinology, The Normal Neuroendocrine System, Progress in Brain Research 2010 Elsevier 321 341
13. C. Labrie, J. Simard, H.F. Zhao, A. Bélanger, G. Pelletier, and F. Labrie Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate Endocrinology 124 6 1989 2745 2754 (Pubitemid 19154105)
14. E.D. Crawford, M.A. Eisenberger, D.G. McLeod, J.T. Spaulding, R. Benson, F.A. Dorr, B.A. Blumenstein, M.A. Davis, and P.J. Goodman A controlled trial of leuprolide with and without flutamide in prostatic carcinoma N. Engl. J. Med. 321 7 1989 419 424 (Pubitemid 19211484)
15. R.A. Janknegt, C.C. Abbou, R. Bartoletti, L. Bernstein-Hahn, B. Bracken, J.M. Brisset, F.C. Da Silva, G. Chisholm, E.D. Crawford, F.M.J. Debruyne, G.D. Dijkman, J. Frick, L. Goedhals, H. Knönagel, and P.M. Venner Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial J. Urol. 149 1993 77 83 (Pubitemid 23095478)
16. C.L. Bennett, T.D. Tosteson, B. Schmitt, P.D. Weinberg, M.S. Ernstoff, and S.D. Ross Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide Prostate Cancer Prostatic Dis. 2 1999 4 8 (Pubitemid 29096321)
17. Prostate Cancer Triallists' Collaborative Group Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials Lancet 355 2000 1491 1498
18. A. Dupont, J.L. Gomez, L. Cusan, M. Koutsilieris, and F. Labrie Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy J. Urol. 150 1993 908 913 (Pubitemid 23241297)
19. M.P. Collinson, F. Daniel, C.J. Tyrrell, and C. Teasdale Response of carcinoma of the prostate to withdrawal of flutamide Br. J. Urol. 72 5 Pt 1 1993 662 663 (Pubitemid 23357202)
20. J. Herrada, P. Dieringer, and C.J. Logothetis Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal J. Urol. 155 2 1996 620 623 (Pubitemid 26023557)
21. W.K. Kelly, and H.I. Scher Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome J. Urol. 149 1993 607 609 (Pubitemid 23094069)
22. W.K. Kelly, S. Slovin, and H.I. Scher Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance Urol. Clin. N. Am. 24 1997 421 431 (Pubitemid 27169267)
23. F. Labrie, and R. Veilleux A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells Prostate 8 1986 293 300 (Pubitemid 16109155)
24. F. Labrie, R. Veilleux, and A. Fournier Low androgen levels induce the development of androgen-hypersensitive cells clones in Shionogi mouse mammary carcinoma cells in culture J. Natl. Cancer Inst. 80 1988 1138 1147
25. F. Labrie Blockade of testicular and adrenal androgens in prostate cancer treatment Nat. Rev. Urol. 8 2 2011 73 85
26. C.D. Chen, D.S. Welsbie, C. Tran, S.H. Baek, R. Chen, R. Vessella, M.G. Rosenfeld, and C.L. Sawyers Molecular determinants of resistance to antiandrogen therapy Nat. Med. 10 1 2004 33 39 (Pubitemid 38524696)
27. H.I. Scher, and C.L. Sawyers Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis J. Clin. Oncol. 23 32 2005 8253 8261 (Pubitemid 46211563)
28. M.E. Taplin, and S.P. Balk Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence J. Cell. Biochem. 91 3 2004 483 490
29. P.F. Mulders, and J.A. Schalken Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer Prostate Cancer Prostatic Dis. 12 3 2009 241 246
30. M.J. McPhaul Mechanisms of prostate cancer progression to androgen independence Best Pract. Res. Clin. Endocrinol. Metab. 22 2 2008 373 388 (Pubitemid 351611961)
31. W.P. Harris, E.A. Mostaghel, P.S. Nelson, and B. Montgomery Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion Nat. Clin. Pract. Urol. 6 2 2009 76 85
32. E.A. Mostaghel, B. Montgomery, and P.S. Nelson Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease Urol. Oncol. 27 3 2009 251 257
33. F. Labrie, J. Simard, S.M. Singh, and B. Candas Estimated potency of Casodex: a problematic design Urology 50 1997 309 313
34. F. Labrie, J. Simard, A. Coquet, G. Leblanc, and B. Candas Reply by the authors Urology 54 1999 195 197
35. J. Simard, S.M. Singh, and F. Labrie Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex and nilutamide on androgen-sensitive parameters Urology 49 1997 580 589 (Pubitemid 27161418)
36. S. Luo, C. Martel, G. Leblanc, B. Candas, S.M. Singh, C. Labrie, J. Simard, A. Bélanger, and F. Labrie Relative potencies of flutamide and Casodex: preclinical studies Endocr. Relat. Cancer 3 1996 229 241 (Pubitemid 26366140)
37. F. Labrie, I. Luthy, R. Veilleux, J. Simard, A. Bélanger, and A. Dupont New concepts on the androgen sensitivity of prostate cancer G.P. Murphy, S. Khoury, R. Kuss, C. Chatelain, L. Denis, Progress in Clinical and Biological Research. Prostate Cancer Part A: Research. Endocrine Treatment and Histopathology 1987 145 172
38. K. Pereira de Jesus-Tran, P.L. Cote, L. Cantin, J. Blanchet, F. Labrie, and R. Breton Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity Protein Sci. 15 5 2006 987 999
39. L. Cantin, F. Faucher, J.F. Couture, K.P. de Jesus-Tran, P. Legrand, L.C. Ciobanu, Y. Frechette, R. Labrecque, S.M. Singh, F. Labrie, and R. Breton Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12 J. Biol. Chem. 282 42 2007 30910 30919 (Pubitemid 350035181)
40. C. Tran, S. Ouk, N.J. Clegg, Y. Chen, P.A. Watson, V. Arora, J. Wongvipat, P.M. Smith-Jones, D. Yoo, A. Kwon, T. Wasielewska, D. Welsbie, C.D. Chen, C.S. Higano, T.M. Beer, D.T. Hung, H.I. Scher, M.E. Jung, and C.L. Sawyers Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 5928 2009 787 790
41. H.I. Scher, T.M. Beer, C.S. Higano, A. Anand, M.E. Taplin, E. Efstathiou, D. Rathkopf, J. Shelkey, E.Y. Yu, J. Alumkal, D. Hung, M. Hirmand, L. Seely, M.J. Morris, D.C. Danila, J. Humm, S. Larson, M. Fleisher, and C.L. Sawyers Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 9724 2010 1437 1446
42. D. Mukherji, C.J. Pezaro, and J.S. De-Bono MDV3100 for the treatment of prostate cancer Expert Opin. Invest. Drugs 21 2 2012 227 233
43. N.J. Clegg, J. Wongvipat, J.D. Joseph, C. Tran, S. Ouk, A. Dilhas, Y. Chen, K. Grillot, E.D. Bischoff, L. Cai, A. Aparicio, S. Dorow, V. Arora, G. Shao, J. Qian, H. Zhao, G. Yang, C. Cao, J. Sensintaffar, T. Wasielewska, M.R. Herbert, C. Bonnefous, B. Darimont, H.I. Scher, P. Smith-Jones, M. Klang, N.D. Smith, E. de Stanchina, N. Wu, O. Ouerfelli, P.J. Rix, R.A. Heyman, M.E. Jung, C.L. Sawyers, and J.H. Hager ARN-509: a novel antiandrogen for prostate cancer treatment Cancer Res. 72 6 2012 1494 1503
44. C. Fee, H. Burstin, J.H. Maselli, and R.Y. Hsia Association of emergency department length of stay with safety-net status JAMA 307 5 2012 476 482
45. C. Pezaro, and G. Attard Prostate cancer in 2011: redefining the therapeutic landscape for CRPC Nat. Rev. Urol. 9 2 2012 63 64
46. M.E. Jung, S. Ouk, D. Yoo, C.L. Sawyers, C. Chen, C. Tran, and J. Wongvipat Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC) J. Med. Chem. 53 7 2010 2779 2796
47. C.L. Sawyers, M.E. Jung, C.D. Chen, S. Ouk, D. Welsbie, C. Tran, J. Wongvipat, D. Yoo, Diarylhydantoin Compounds, U.S. Patent Appl. 2007/0004753 (2007).
48. C. Martel, L. Provencher, X. Li, A. St-Pierre, G. Leblanc, S. Gauthier, Y. Mérand, and F. Labrie Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors J. Steroid Biochem. Mol. Biol. 64 1998 199 205 (Pubitemid 28200993)
49. S. Luo, C. Martel, A. Sourla, S. Gauthier, Y. Mérand, A. Bélanger, C. Labrie, and F. Labrie Comparative effects of 28-day treatment with the new antiestrogen EM-800 and tamoxifen on estrogen-sensitive parameters in the intact mouse Int. J. Cancer 73 1997 381 391 (Pubitemid 27508901)
50. J. Asselin, R. Mélançon, G. Moachon, and A. Bélanger Characteristics of binding to estrogen, androgen, progestin and glucocorticoid receptors in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and their hormonal control Cancer Res. 40 1980 1612 1622 (Pubitemid 10102007)
51. F. Labrie, and R. Veilleux Maintenance of androgen responsiveness by glucocorticoids in Shionogi mammary carcinoma cells in culture J. Natl. Cancer Inst. 80 1988 966 970
52. F. Labrie, R. Veilleux, and A. Fournier Glucocorticoids stimulate the growth of mouse mammary carcinoma Shionogi cells in culture Mol. Cell. Endocrinol. 58 1988 207 211
53. J. Simard, S. Dauvois, D.E. Haagensen, C. Lévesque, Y. Mérand, and F. Labrie Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer Endocrinology 126 1990 3223 3231 (Pubitemid 20216586)
54. H. Qi, Y. Labrie, J. Grenier, A. Fournier, C. Fillion, and C. Labrie Androgens induce expression of SPAK, a STE20/SPS1-related kinase, in LNCaP human prostate cancer cells Mol. Cell. Endocrinol. 182 2001 181 192 (Pubitemid 32758771)
55. F. Labrie, A. Bélanger, P. Bélanger, R. Bérubé, C. Martel, L. Cusan, J.L. Gomez, B. Candas, I. Castiel, V. Chaussade, C. Deloche, and J. Leclaire Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women J. Steroid Biochem. Mol. Biol. 99 2006 182 188 (Pubitemid 43766081)
56. J. Asselin, F. Labrie, Y. Gourdeau, C. Bonne, and J.P. Raynaud Binding of [3H]methyltrienolone (R1881) in rat prostate and human benign prostatic hypertrophy (BPH) Steroids 28 1976 449 459 (Pubitemid 8002196)
57. I. Luthy, and F. Labrie Development of androgen resistance in mouse mammary tumor cells can be prevented by the antiandrogen flutamide Prostate 10 1 1987 89 94 (Pubitemid 17037653)
58. Y. de Launoit, R. Veilleux, M. Dufour, J. Simard, and F. Labrie Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells Cancer Res. 51 19 1991 5165 5170
59. J. Veldscholte, C. Ris-Stalpers, G.G. Kuiper, G. Jenster, C. Berrevoets, E. Claassen, H.C. van Rooij, J. Trapman, A.O. Brinkmann, and E. Mulder A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens Biochem. Biophys. Res. Commun. 173 1990 534 540
60. J. Simard, R. Veilleux, Y. de Launoit, D.E. Haagensen, and F. Labrie Stimulation of apolipoprotein D secretion by steroids coincides with inhibition of cell proliferation in human LNCaP prostate cancer cells Cancer Res. 51 1991 4336 4342
61. H. Kawata, S. Arai, T. Nakagawa, N. Ishikura, A. Nishimoto, H. Yoshino, T. Shiraishi, K. Tachibana, R. Nakamura, and H. Sato Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291 Prostate 71 12 2011 1344 1356
62. D. Moras, and H. Gronemeyer The nuclear receptor ligand-binding domain: structure and function Curr. Opin. Cell Biol. 10 3 1998 384 391 (Pubitemid 28287050)
63. A.M. Brzozowski, A.C. Pike, Z. Dauter, R.E. Hubbard, T. Bonn, O. Engstrom, L. Ohman, G.L. Greene, J.A. Gustafsson, and M. Carlquist Molecular basis of agonism and antagonism in the oestrogen receptor Nature 389 6652 1997 753 758 (Pubitemid 27458965)
64. J.S. Sack, K.F. Kish, C. Wang, R.M. Attar, S.E. Kiefer, Y. An, G.Y. Wu, J.E. Scheffler, M.E. Salvati, S.R. Krystek Jr., R. Weinmann, and H.M. Einspahr Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone Proc. Natl. Acad. Sci. U.S.A. 98 9 2001 4904 4909 (Pubitemid 32397055)
65. E. Estebanez-Perpina, J.M. Moore, E. Mar, E. Delgado-Rodrigues, P. Nguyen, J.D. Baxter, B.M. Buehrer, P. Webb, R.J. Fletterick, and R.K. Guy The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor J. Biol. Chem. 280 9 2005 8060 8068 (Pubitemid 40349704)
66. B. He, R.T. Gampe Jr., A.J. Kole, A.T. Hnat, T.B. Stanley, G. An, E.L. Stewart, R.I. Kalman, J.T. Minges, and E.M. Wilson Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance Mol. Cell 16 3 2004 425 438 (Pubitemid 39504796)
67. E. Hur, S.J. Pfaff, E.S. Payne, H. Gron, B.M. Buehrer, and R.J. Fletterick Recognition and accommodation at the androgen receptor coactivator binding interface PLoS Biol. 2 9 2004 E274
68. C.E. Bohl, Z. Wu, D.D. Miller, C.E. Bell, and J.T. Dalton Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design J. Biol. Chem. 282 18 2007 13648 13655 (Pubitemid 47100516)
69. M. Plante, S. Lapointe, and F. Labrie Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice J. Steroid Biochem. 31 1988 61 64
70. C. Labrie, L. Cusan, M. Plante, S. Lapointe, and F. Labrie Analysis of the androgenic activity of synthetic progestins currently used for the treatment of prostate cancer J. Steroid Biochem. 28 1987 379 384 (Pubitemid 18015483)
71. I.A. Luthy, D.J. Bégin, and F. Labrie Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture J. Steroid Biochem. 31 1988 845 852 (Pubitemid 19006901)
72. J.F. Caubet, T.D. Tosteson, E.W. Dong, E.M. Naylon, G.W. Whiting, M.S. Ernstoff, and S.D. Ross Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens Urology 49 1997 71 78 (Pubitemid 27043101)
73. M.E. Taplin Drug insight: role of the androgen receptor in the development and progression of prostate cancer Nat. Clin. Pract. Oncol. 4 4 2007 236 244
74. T.H. van der Kwast, J. Schalken, and J.A. Ruizeveld de Winter Androgen receptors in endocrine-therapy-resistant human prostate cancer Int. J. Cancer 48 1991 189 193
75. J.A. Ruizeveld de Winter, P.J. Janssen, H.M. Sleddens, M.C. Verleun-Mooijman, J. Trapman, A.O. Brinkmann, A.B. Santerse, F.H. Schroder, and T.H. van der Kwast Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer Am. J. Pathol. 144 4 1994 735 746 (Pubitemid 24172062)
76. M.H. Lévesque, M. El-Alfy, L. Cusan, and F. Labrie Androgen receptor as a potential sign of prostate cancer metastasis Prostate 69 15 2009 1704 1711
77. T.H. van der Kwast, B. Tetu, Y. Fradet, A. Dupont, J. Gomez, L. Cusan, P. Diamond, and F. Labrie Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy Prostate 28 1996 227 231 (Pubitemid 26119114)
78. C. Labrie, A. Bélanger, and F. Labrie Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate Endocrinology 123 1988 1412 1417
79. F. Labrie, V. Luu-The, A. Bélanger, S.-X. Lin, J. Simard, and C. Labrie Is DHEA a hormone? Starling review J. Endocrinol. 187 2005 169 196
80. T. Nishiyama, Y. Hashimoto, and K. Takahashi The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer Clin. Cancer Res. 10 21 2004 7121 7126 (Pubitemid 39487695)
81. E.A. Mostaghel, S.T. Page, D.W. Lin, L. Fazli, I.M. Coleman, L.D. True, B. Knudsen, D.L. Hess, C.C. Nelson, A.M. Matsumoto, W.J. Bremner, M.E. Gleave, and P.S. Nelson Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer Cancer Res. 67 10 2007 5033 5041 (Pubitemid 46910214)
82. L.J. Denis, F. Keuppens, P.H. Smith, P. Whelan, J.L. Carneiro de Moura, D. Newling, A. Bono, and R. Sylvester Maximal androgen blockade: final analysis of EORTC Phase III trial 30853 Eur. Urol. 33 1998 144 151 (Pubitemid 28073756)
83. J.A. Maddy, W.W. Winternitz, and H. Norrell Cryohypophysectomy in the management of advanced prostatic cancer Cancer 28 2 1971 322 328
84. J.R. Drago, R.J. Santen, A. Lipton, T.J. Worgul, H.A. Harvey, A. Boucher, A. Manni, and T.J. Rohner Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma Cancer 53 7 1984 1447 1450 (Pubitemid 14166552)
85. R. Murray, and P. Pitt Treatment of advanced prostatic cancer, resistant to conventional therapy, with aminoglutethimide Eur. J. Cancer Clin. Oncol. 21 4 1985 453 458 (Pubitemid 15076950)
86. F. Labrie, A. Dupont, M. Giguère, J.P. Borsanyi, L.Y.G. Monfette, J. Emond, and N. Bergeron Benefits of combination therapy with flutamide in patients relapsing after castration Br. J. Urol. 61 1988 341 346
87. J.E. Fowler Jr., and W.F. Whitmore Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone J. Urol. 126 3 1981 372 375 (Pubitemid 11061000)
88. G. Attard, A.H. Reid, R. A'Hern, C. Parker, N.B. Oommen, E. Folkerd, C. Messiou, L.R. Molife, G. Maier, E. Thompson, D. Olmos, R. Sinha, G. Lee, M. Dowsett, S.B. Kaye, D. Dearnaley, T. Kheoh, A. Molina, and J.S. de Bono Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J. Clin. Oncol. 27 23 2009 3742 3748